Cite

HARVARD Citation

    Somaiah, N. et al. (2022). Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet oncology. 23 (9), pp. 1156-1166. [Online]. 
  
Back to record